Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physician diagnosed chronic urticaria
- Currently be receiving omalizumab therapy for the treatment of chronic idiopathic urticaria and be well controlled with a USS <25
Exclusion Criteria:
- Not capable of informed consent.
- Not capable of answering the questionnaire.
- Subjects with a pure physical urticaria.
- Pregnant or lactating women.
- Subjects with hypercalcemia (calcium > 10.3 mg/dl) or renal insufficiency (GFR <50 ml/min).
- Subjects with prior anaphylaxis to omalizumab.
- Currently taking high dose vitamin D supplementation.
- Prior high dose vitamin D supplementation for urticaria with failure.
- Baseline 25(OH)D >80 ng/ml
- Subjects with sarcoidosis, hyperparathyroidism, histoplasmosis, lymphoma or tuberculosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: High Dose Vitamin D
Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
|
High Dose of 4,000 IU/day.
Standard of care dose.
Other Names:
|
|
Active Comparator: Low Dose Vitamin D
Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
|
Standard of care dose.
Other Names:
Low Dose of 400 IU/day.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in total Urticaria Severity Score (USS)
Time Frame: Change from Baseline to Month 6
|
The USS is a questionnaire which is used to measure urticaria severity.
The questionnaire is comprised on 9 questions with each question having 7 total responses on a likert-type scale.
Responses to each question range from 0 to 7.
|
Change from Baseline to Month 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects restarted on Omalizumab
Time Frame: 8 Months
|
Number of participants restarted on Omalizumab after coming off it at Month 4
|
8 Months
|
|
Change in total Urticaria Severity Score (USS)
Time Frame: Change from Baseline to Month 8
|
Change from Baseline to Month 8
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Selina Gierer, D.O., University of Kansas Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Physiological Effects of Drugs
- Micronutrients
- Anti-Asthmatic Agents
- Respiratory System Agents
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Anti-Allergic Agents
- Vitamin D
- Cholecalciferol
- Vitamins
- Omalizumab
- Ergocalciferols
Other Study ID Numbers
Other Study ID Numbers
- STUDY00002729
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.